Van De Kerkhof, P. C. M. Et Al. 2015. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. LANCET , vol.386, no.9993 , 552-561.

Van De Kerkhof, P. C. M., Strohal, R., Kubanov, A., Valenzuela, F., Lee, J., Yakusevich, V., ... Chimenti, S.(2015). Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. LANCET , vol.386, no.9993, 552-561.

Van De Kerkhof, Peter Et Al. "Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial," LANCET , vol.386, no.9993, 552-561, 2015

Van De Kerkhof, Peter C. Et Al. "Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial." LANCET , vol.386, no.9993, pp.552-561, 2015

Van De Kerkhof, P. C. M. Et Al. (2015) . "Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial." LANCET , vol.386, no.9993, pp.552-561.

@article{article, author={Peter C. M. Van De Kerkhof Et Al. }, title={Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial}, journal={LANCET}, year=2015, pages={552-561} }